Venture Global and Atlantic-SEE Announce Expansion of Long-Term LNG Sales and Purchase Agreement with Greece

 Deal doubles quantity of US LNG to be supplied by Venture Global, expanding existing partnership to bolster Central and Eastern European energy security

Builds on Venture Global’s regasification capacity investment in the Alexandroupolis LNG import terminal to supply U.S. LNG to the region

 

(BUSINESS WIRE)--Today, Venture Global, Inc. (NYSE: VG) and ATLANTIC – SEE LNG TRADE S.A. of Greece announced an expansion of their existing Sales and Purchase Agreement (SPA) for the purchase of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. Under the deal, Atlantic-SEE is doubling their existing contract with Venture Global from a minimum of 0.5 million tonnes per annum (MTPA) to 1.0 million tonnes per annum (MTPA).

Atlantic-SEE LNG is a newly formed joint venture announced in November at the 6th Partnership for Transatlantic Energy Cooperation (PTEC) conference hosted in Athens, Greece between Greek companies AKTOR Group and DEPA Commercial. The announcement of this expanded supply agreement follows Venture Global’s previously announced investment in regasification capacity at the Alexandroupolis LNG import terminal in Greece, which currently accounts for approximately 25% of the terminal’s total capacity. The Alexandroupolis LNG FSRU receiving terminal and South-North ‘Vertical Corridor’ will be essential to enhancing Central and Eastern European energy security by providing a new route to bring affordable and reliable U.S. natural gas into the region.

“Venture Global is honored to announce this expanded partnership which reinforces our shared commitment to energy security, supply diversification, and economic growth, while advancing the strategic energy relationship between the United States and Europe,” said Venture Global CEO Mike Sabel. “The Vertical Corridor has emerged as a vital energy hub for the region, and our continued investment in infrastructure such as the Alexandroupolis terminal is helping create new pathways for secure, reliable energy supply across Central and Eastern Europe. We are grateful for the leadership of President Trump, Secretary Burgum, Secretary Wright, Ambassador Guilfoyle, and officials across both sides of the Atlantic whose support continues to strengthen transatlantic energy cooperation and expand access to U.S. LNG around the world.”

“The expansion of our commercial agreement with Venture Global reflects the ambition and solid ground of our long-term strategic plan on LNG and the potential of the vertical corridor, which can provide alternatives and energy security across Central and Eastern Europe. It also highlights the growing importance of the transatlantic energy cooperation between Greece and the United States that will benefit the entire region,” said Alexandros Exarchou, CEO of Atlantic SEE LNG Trade. “The geopolitical development has offered us the historic opportunity to operate as an energy hub between continents, and we aspire to build on this momentum and offer our customers long-term, sustainable, and predictable energy safety.”

“Today’s agreement marks the successful transition from vision to action," said Konstantinos Xifaras, Chairman of Atlantic SEE LNG Trade. “By doubling the volumes secured under this agreement, we are creating a stronger foundation for reliable and predictable LNG supplies across the region, while translating strategic planning into concrete commercial outcomes. This agreement reflects the value of long-term partnerships and reinforces the growing role of transatlantic energy cooperation in supporting regional energy security and resilience.”

About Venture Global

Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. The company’s first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.

About Atlantic SEE LNG Trade

ATLANTIC – SEE LNG TRADE is a company in which AKTOR Group of Companies holds a 60% stake and DEPA Commercial holds 40%, respectively. Its goal is to import Liquefied Natural Gas (LNG) into Greece and trade it across Eastern and Southeastern Europe via the Vertical Energy Corridor, thereby contributing to Europe's energy supply security and strengthening Transatlantic Cooperation.

Forward-looking Statements

This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical facts, included herein are “forward-looking statements.” In some cases, forward-looking statements can be identified by terminology such as “may,” “might,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology.

These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include statements about our future performance, our contracts, our anticipated growth strategies and anticipated trends impacting our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include our need for significant additional capital to construct and complete future projects and related assets, and our potential inability to secure such financing on acceptable terms, or at all; our potential inability to accurately estimate costs for our projects, and the risk that the construction and operations of natural gas pipelines and pipeline connections for our projects suffer cost overruns and delays related to obtaining regulatory approvals, development risks, labor costs, unavailability of skilled workers, operational hazards and other risks; the uncertainty regarding the future of global trade dynamics, international trade agreements and the United States’ position on international trade, including the effects of tariffs; our dependence on our EPC and other contractors for the successful completion of our projects, including the potential inability of our contractors to perform their obligations under their contracts; various economic and political factors, including opposition by environmental or other public interest groups, or the lack of local government and community support required for our projects, which could negatively affect the permitting status, timing or overall development, construction and operation of our projects; and risks related to other factors discussed under “Item 1A.—Risk Factors” of our annual report on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (“SEC”) and any subsequent reports filed with the SEC.

Any forward-looking statements contained herein speak only as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date. We undertake no obligation to update these statements to reflect subsequent events or circumstances, except as may be required by law.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611230438/en/

Permalink

https://www.aetoswire.com/en/news/1206202655636

Contacts

Investor contact:

Ben Nolan

IR@ventureglobalLNG.com

Media contact:

Shaylyn Hynes

press@ventureglobalLNG.com

 

Venture Global Announces Closing of $2.25 Billion of Senior Secured Notes

 ARLINGTON, Va. - Friday, 12. June 2026 AETOSWire Print 

(BUSINESS WIRE)--Venture Global LNG, Inc. (“Venture Global”) announced today that its wholly-owned subsidiary, Venture Global LNG, Inc. (the “Issuer”) has closed its offering of $1.125 billion aggregate principal amount of its 6.375% senior secured notes due 2034 (the “2034 Notes”) and $1.125 billion aggregate principal amount of its 6.625% senior secured notes due 2036 (the “2036 Notes” and, together with the 2034 Notes, the “Notes”). The Issuer used the gross proceeds from the offering to redeem all of the Issuer’s outstanding 8.125% senior secured notes due 2028 (the “Existing 2028 Notes”) and used cash on hand to pay the redemption premium and related fees and expenses for the offering and the redemption.

The 2034 Notes will mature on December 15, 2034, and the 2036 Notes will mature on June 15, 2036. The Notes were issued at par. The Notes will initially not be guaranteed by any of the Issuer’s subsidiaries. In the future, certain of the Issuer’s subsidiaries that incur or guarantee certain amounts of indebtedness will also guarantee the Notes, except during any period where the Notes are rated investment grade by specified rating agencies (the “Suspension Period”). The Notes and any future guarantees of the Notes will be secured on a first-priority basis by the same lien on the collateral that secures the Issuer’s existing notes and revolving credit facility, subject to certain liens permitted under the indenture that will govern the Notes. The Notes will cease to be secured during any Suspension Period.

The Notes were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdictions, and the Notes may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Notes, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Venture Global

Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. The company’s first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.

Forward-Looking Statements

This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements included herein that are not statements of historical facts are “forward-looking statements.” In some cases, forward-looking statements can be identified by terminology such as “may,” “might,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology.

These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, expectations regarding the development, construction, commissioning and completion of our projects, expectations regarding sales of LNG cargos, estimates of the cost of our projects and schedule to construct and commission our projects, our anticipated growth strategies and anticipated trends impacting our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including: our potential inability to maintain profitability, maintain positive operating cash flow and ensure adequate liquidity in the future, including as a result of the significant uncertainty in our ability to generate proceeds and the amount of proceeds that will regularly be received from sales of uncontracted commissioning cargos and excess cargos due to volatility and variability in the LNG markets; our need for significant additional capital to construct and complete projects, including some of our existing projects, future projects, potential bolt-on expansions and related assets, and our potential inability to secure such financing on acceptable terms, or at all; our potential inability to construct or operate all of our proposed LNG facilities or pipelines or any additional LNG facilities or pipelines beyond those currently planned, including any of the bolt-on expansion opportunities which we have identified, and to produce LNG in excess of our nameplate capacity, which could limit our growth prospects, including as a result of delays in obtaining regulatory approvals or inability to obtain requisite regulatory approvals to complete construction during our estimated development periods; significant operational risks related to our natural gas liquefaction and export projects, including the our existing projects and any potential bolt-on expansions, any future projects we develop, our pipelines, our LNG tankers, and our regasification terminal usage rights; our potential inability to accurately estimate costs for our projects, and the risk that the construction and operations of natural gas pipelines and pipeline connections for our projects suffer cost overruns and delays related to obtaining regulatory approvals, development risks, labor costs, unavailability of skilled workers, operational hazards and other risks; the uncertainty regarding the future of international trade agreements and the United States’ position on international trade, including the effects of tariffs as well as the effects of ongoing legal challenges to tariffs and reimbursements of tariffs; our current and potential involvement in disputes and legal proceedings, including the arbitrations and other proceedings currently pending against us and the possibility and magnitude of negative outcomes in any such dispute or proceeding and the potential impact thereof on our results of operations, liquidity and our existing contracts; our potential inability to enter into the necessary contracts to construct our projects, or any potential bolt-on expansion, on a timely basis or on terms that are acceptable to us; our potential inability to enter into Contracted SPAs with customers for, or to otherwise sell, an adequate portion of the total expected nameplate capacity at our projects, or any potential bolt-on expansion, or any future projects we develop; our dependence on our EPC contractors and suppliers for the successful completion of our projects and delivery of our LNG tankers, including the potential inability of our contractors to perform their obligations under their contracts; various economic and political factors, including opposition by environmental or other public interest groups, or the lack of local government and community support required for our projects, which could negatively affect the permitting status, timing or overall development, construction and operation of our projects; the effects of FERC regulation on our interstate natural gas pipelines and their FERC gas tariffs; the risk that the natural gas liquefaction system and mid-scale design we utilize at our projects will not achieve the level of performance or other benefits that we anticipate; potential additional risks arising from the duration of and the phased commissioning start-up of our projects; the potential risk that our customers or we may terminate our SPAs if certain conditions are not met or for other reasons; potential decreases in the price of natural gas and its related impact on our ability to pay the cost of gas transportation, the payment of a premium by us for feed gas relative to the contractual price we charge our customers, or other impacts to the price of natural gas resulting from inflationary pressures, including from the disruption in international oil and natural gas supply chains caused by the ongoing war in Iran and the closure of the Strait of Hormuz; the potential negative impacts of seasonal fluctuations on our business; the risks related to the development and/or contracting for additional gas transportation capacity to support the operation and expansion capacity of our LNG projects; the risks related to the management and operation of our LNG tanker fleet and our future regasification terminal usage rights; the potential effects of existing and future environmental and similar laws and governmental regulations on compliance costs, operating and/or construction costs and restrictions; our potential inability to obtain, maintain or comply with necessary permits or approvals from governmental and regulatory agencies on which the construction of our projects depends, including as a result of opposition by environmental and other public interest groups; our indebtedness levels, and the fact that we may be able to incur substantially more indebtedness, which may increase the risks created by our substantial indebtedness. For more information on these and other factors that could cause our results to differ materially from expected results, please refer to the risks and uncertainties discussed in our Annual Report on Form 10-K for the year ended December 31, 2025. In addition, please note that the date of this press release is June 11, 2026, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. We undertake no obligation to update these statements as a result of new information or future events.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611109916/en/

Permalink

https://www.aetoswire.com/en/news/1206202655638

Contacts

Investor Contact:

Ben Nolan

IR@ventureglobalLNG.com

Media Contact:

Shaylyn Hynes

press@ventureglobalLNG.com

Visa Announces New AI, Stablecoin and Token Innovations to Power Intelligent, Programmable Commerce at Visa Payments Forum

 New Agent Scoring, Agentic Registry and Large Transaction Model capabilities, stablecoin settlement and token enhancements support the next gen of digital commerce

 

(BUSINESS WIRE)--At Visa Payments Forum 2026, Visa (NYSE: V) today announced new AI, stablecoin and token capabilities designed to help clients unlock the next generation of commerce. These innovations reflect a simple objective: ensuring trust, security and control evolve alongside increasingly fast, automated and intelligent commerce experiences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610464331/en/

In a keynote presentation, Jack Forestell, Chief Product & Strategy Officer at Visa, outlined how two foundational shifts—artificial intelligence and stablecoins—are transforming both the front end and back end of money movement, and how Visa is enabling clients to participate.

“AI is transforming the front end of commerce. Stablecoins are reshaping the back end,” said Forestell. “Visa’s role is to enable it to work securely, reliably and at global scale, for every participant in the ecosystem.”

Powering the Front End of Commerce—and How It Gets Built—with AI

Visa detailed how AI is reshaping how transactions are initiated, authorized and trusted—while also accelerating how new commerce experiences are designed, developed and delivered, particularly as AI agents increasingly act on behalf of consumers and businesses.

Visa Intelligent Commerce, the company’s platform for agentic commerce, provides the trust, controls and connectivity needed for AI agents to securely discover, initiate and complete transactions.

To support this shift, Visa is working across the ecosystem—partnering with leading AI platforms, enabling new merchant capabilities and building infrastructure to ensure agent-initiated transactions are transparent and trusted, including:

Agent Score: Created with New Generation, it allows merchants to evaluate their websites for agentic commerce readiness—specifically, whether AI agents can navigate, understand and complete tasks on a merchant’s website.

Agentic Directory: Merchants need to know which agents can be trusted to transact on their sites, and agents need confidence that they are interacting with legitimate merchants. The directory includes agents and merchants that Visa has verified as legitimate participants in agentic commerce.

OpenAI Partnership: a strategic collaboration with OpenAI to enable secure Visa payments within agentic commerce, enabling seamless and trusted payments across OpenAI. Through the partnership, Visa will provide its global network, credentialing capabilities and security infrastructure to support agentic commerce experiences, helping consumers and businesses interact and transact with confidence.

Large Transaction Model: An AI model trained on billions of transactions to improve fraud detection while increasing authorization performance and reducing false declines—a trade-off the industry has struggled with for years.

Visa also demonstrated early development concepts from its Crypto Labs and developer teams. This included a Command Line Interface proof of concept that lets AI agents pay for digital services directly in the terminal using Visa’s tokenized credentials.

“We believe a growing share of creation and transactions will be led by developers using AI tools,” said Forestell. “We are working with the industry to make cards the best way to pay in the Command Line.”

Enhancing Tokens for AI-Driven Commerce

Visa announced significant enhancements to its tokens, focused on bringing more data, context and assurance into the credentials used in digital commerce.

Today, tokens already carry a highly secure data set purpose-built for digital payments. As commerce extends to new channels and agents, Visa is enriching the data to provide more details on the transaction type, where the token is being used and who is making the payment.

A second key advancement is a token assurance signal. Token use is evaluated throughout its lifecycle—based on provisioning and behavioral history—to generate a signal of trust behind each transaction.

These enhancements provide issuers with stronger signals for authorization decisions, helping reduce false declines for merchants while minimizing friction for consumers.

Designed for AI-driven commerce, these developments embed identity, permissions and behavioral signals more deeply into credentials—allowing trust to travel with the transaction across devices, channels and use cases, including those initiated autonomously by AI agents.

Modernizing the Back End of Money Movement with Stablecoins

Visa also shared progress in modernizing settlement and value transfer through stablecoins and blockchain-based infrastructure.

Tokenized Deposits: Visa announced it will build the technology layer that can allow banks to turn traditional deposits into programmable, always-on digital money. This gives banks a way to match the speed and flexibility of stablecoins while keeping funds on balance sheet.

Stablecoin Settlement: Visa is expanding stablecoin settlement pilots across multiple regions, blockchains and currencies. Building on its first stablecoin settlement pilots in early 2025, Visa has moved billions of dollars in stablecoins across VisaNet, with an annualized run rate of approximately $7 billion as of March 2026. With issuing banks already settling seven days a week onchain with Visa, Visa is also working to extend seven-day settlement to include acquirers, increasing flexibility and frequency across the entire ecosystem.

Stablecoin-Linked Cards: Visa continues to expand stablecoin-linked card programs, enabling consumers and businesses to spend stablecoin balances anywhere Visa is accepted. With more than 160 programs live or in development globally, adoption is expected to accelerate.

Helping Clients Modernize Without Disruption

Across these innovations, Visa emphasized a consistent theme from clients: modernization is essential, but full system replacement is not practical. Visa is addressing this with modular, cloud-native capabilities that integrate with existing infrastructure and enable banks, fintechs, acquirers and merchants to modernize at their own pace.

For issuers, the Pismo core banking platform enables flexible, real-time banking and processing capabilities with a phased path away from traditional systems.

For acquirers and merchants, Unified Checkout provides a consistent way to accept both card and non-card payments through a single orchestration layer—supporting evolving commerce models, including AI-driven transactions. Visa Intelligent Authorization uses real-time network signals and advanced models to help acquirers and their merchants optimize authorization approvals and capture incremental spend that might otherwise be declined.

Leading the Evolution of Commerce

Taken together, the announcements at Visa Payments Forum reflect a clear vision: Visa is becoming the platform that connects AI, programmable money, modern infrastructure and global trust so clients can win now and be ready for what’s next.

“History is filled with innovations that never reached scale,” said Forestell. “What determines success is trust, security and global reach. That’s what Visa brings to every new era of commerce – and what we’re building for the future.”

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610464331/en/

Permalink

https://aetoswire.com/en/news/1106202655580

Contacts

Media Contacts

Conor Febos - press@visa.com

Jackie Dresch - press@visa.com

 

Bitget Continues Stock Spot Expansion With 30 New Listings Across Leading Market Themes

 

VICTORIA, Seychelles - Thursday, 11. June 2026

(GLOBE NEWSWIRE) -- Bitget, the world’s largest Universal Exchange, has expanded its stock spot lineup with the listing of 30 new stock spot assets, further widening users’ access to traditional market opportunities under the recent launch of Stock 2.0. The newly listed assets include rNASA, rBMNR, rDIS, rROKU, and rLCID, and were made available on June 8, 2026.

The latest additions cover a diverse range of companies and investment themes, spanning space innovation, entertainment, consumer brands, enterprise technology, healthcare, defense, cloud infrastructure, education technology, and electric vehicles. The newly supported assets include Tema Space Innovators ETF, BitMine Immersion Technologies, AbbVie, Automatic Data Processing, BlackSky Technology, BWX Technologies, CAVA Group, Celsius Holdings, Cognex, CRISPR Therapeutics, The Walt Disney Company, DigitalOcean, Duolingo, Guidewire Software, Himax Technologies, Hewlett Packard Enterprise, The Coca-Cola Company, Lucid Group, and Lockheed Martin, among others.

Following the recent integration of 49 U.S. equities and ETFs, as well as the expansion of the Bitget Unified Trading Account to include tokenized stocks as margin assets, this latest update provides users with even broader exposure to established global corporations and emerging growth companies across high-activity market sectors. Bitget enhances the accessibility of traditional financial products alongside its robust crypto and market instrument suites, enabling a more comprehensive investment experience through a single, unified platform.

The addition further strengthens Bitget's Universal Exchange strategy, which brings together crypto assets, stocks, ETFs, commodities, foreign exchange products, precious metals, derivatives, and tokenized financial instruments within a unified trading environment. The platform currently offers access to more than 100 tokenized stocks and ETFs, alongside a growing suite of traditional financial products designed to help users navigate opportunities across global markets.

For more information, visit here.

About Bitget

 

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

Contacts :

For media inquiries, please contact: media@bitget.com

Andersen Consulting Strengthens Digital Transformation and Cybersecurity Offerings with HeadMind Partners

 (BUSINESS WIRE)--Andersen Consulting enters into a Collaboration Agreement with HeadMind Partners, a leading European consultancy specializing in cybersecurity, digital transformation, and AI, strengthening the organization’s platform.

With its unique combination of 25 years’ business experience, technology and data expertise, HeadMind Partners enables its clients, large companies from both private and public sectors, to strengthen their digital and cyber resilience, enhance their operational efficiency, and build robust and sovereign AI solutions. Headquartered in Paris and operating in France and Belgium to date, the company draws on multidisciplinary teams of 500 cybersecurity experts, 70 AI engineers and 400 digital transformation specialists to provide value-creating and seamless cybersecurity, AI and digital transformation solutions. HeadMind Partners serves a diverse and renowned client portfolio across financial services, industry, energy, luxury and the public sector.

“Collaborating with Andersen Consulting connects us to a truly global organization,” said Guy-Hubert Bourgeois, chairman and CEO of HeadMind Partners. “By integrating our cybersecurity, AI, and digital-program solutions with Andersen’s global platform, we look forward to leveraging synergies with the member and collaborating firms to continuously elevate a client offering designed to deliver sustained value.”

“Our collaboration with HeadMind enhances our ability to address the growing digital, cyber, and operational challenges facing our clients,” said Mark L. Vorsatz, global chairman and CEO of Andersen. “HeadMind’s depth in these areas strengthens our global capabilities and supports our commitment to delivering seamless, integrated consulting services across markets and industries.”

Andersen Consulting is a global consulting practice providing a comprehensive suite of services spanning corporate strategy, business, technology, and AI transformation, as well as human capital solutions. Andersen Consulting integrates with the multidimensional service model of Andersen Global, delivering world-class consulting, tax, legal, valuation, global mobility, and advisory expertise on a global platform with more than 50,000 professionals worldwide and a presence in over 1,000 locations through its member firms and collaborating firms. Andersen Consulting Holdings LP is a limited partnership and provides consulting solutions through its member firms and collaborating firms around the world.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611951863/en/

Permalink

https://www.aetoswire.com/en/news/1106202655617

Contacts

mediainquiries@Andersen.com

Bitget CFD Rolls Out Zero-Fee Mode Amid Daily Volume Growth Toward $10B

 

VICTORIA, Seychelles - Thursday, 11. June 2026

 

Bitget, the world’s largest Universal Exchange (UEX), today announced the launch of Zero-Fee Mode for Bitget CFD, introducing a commission-free account option designed to make CFD trading more flexible, transparent, and accessible.

The launch comes as Bitget CFD continues to scale rapidly, with daily trading volume reaching $8 billion in May and moving closer to the $10 billion milestone. This growth reflects rising demand for multi-asset trading access, as users increasingly seek efficient ways to trade global markets within a unified platform.

Bitget CFD now offers a dual-account structure that gives users greater control over how they trade. The existing ECN Mode remains available for professional, short-term, and high-frequency traders who prefer tighter spreads with volume-based commissions, while the new Zero-Fee Mode is designed for users who favor a more straightforward cost structure with standard spreads and no trading commissions.

The update is driven by growing user demand and feedback around more intuitive trading experiences. Rather than imposing a single model, Bitget CFD now gives users the flexibility to choose the account type that best matches their capital size, trading strategy, experience level, and personal preferences

Multi-asset access is becoming the new standard for trading platforms, and CFD is central to how Bitget is delivering that future,” said Gracy Chen, CEO of Bitget. “By introducing Zero-Fee Mode, we are providing users with greater flexibility to engage in global markets, further advancing our mission to make financial opportunities more accessible within a single, integrated ecosystem

This introduction follows a string of successes for Bitget CFD, including its debut industry honor as the Best Global Multi-Asset Trading Platform at the Online Trading Expo. Previously, the platform noted that non-crypto assets accounted for up to 40% of trading activity on certain days this year. Gold and U.S. indices, such as the NAS100, remain the platform’s two most popular trading products, driving overall volume growth.

Within Bitget’s UEX vision, Bitget CFD plays a key role in connecting crypto and traditional market access through one integrated trading ecosystem. The addition of Zero-Fee Mode strengthens Bitget’s broader effort to make multi-asset trading more accessible, flexible, and aligned with different user needs.
For more information about the launch, visit here.
 

About Bitget
Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 100+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships with LALIGA and MotoGP™. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry's lowest fees and highest liquidity across 150 regions worldwide.
For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord
For media inquiries, please contact: media@bitget.com
Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.
 

Contacts :

For media inquiries, please contact: media@bitget.com

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

 Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study

More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib

Safety profile was consistent with previous studies with no new safety signals identified

 

(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO).

In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified.

Perspectives on head-to-head zasocitinib study

“In this head-to-head study, zasocitinib clearly demonstrated superior skin clearance compared with deucravacitinib, highlighting clinically meaningful differences within the oral treatment class,” said Linda Stein Gold, M.D., Director of Dermatology Clinical Research at Henry Ford Health and principal investigator for the LATITUDE Atlas study. “As expectations for oral therapies continue to rise, these findings support the potential of zasocitinib to help transform what patients and physicians can expect from an oral option in plaque psoriasis.”

“These head-to-head results build on the strong efficacy seen across our Phase 3 program, with more than 35% of zasocitinib-treated patients achieving complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib – and separation from the deucravacitinib curve as early as week 8,” said Chinwe Ukomadu, MD, PhD, senior vice president and head, Gastrointestinal & Inflammation Therapeutic Area Unit at Takeda. “Together, these findings reinforce the promise of zasocitinib to deliver rapid and durable skin clearance in a convenient once-daily pill and demonstrate the transformative potential of highly selective and potent TYK2 inhibition for patients suffering with plaque psoriasis.”

Next steps for head-to-head study and development program for zasocitinib in psoriasis

Takeda intends to present detailed data from the head-to-head study at upcoming medical congresses, building on landmark Phase 3 LATITUDE PsO results (3001 and 3002 studies) recently presented at the American Academy of Dermatology Annual Meeting. The company is on track to submit a New Drug Application for plaque psoriasis with the United States Food and Drug Administration and other regulatory authorities starting this fiscal year.

About Plaque Psoriasis

Psoriasis is a chronic, systemic immune-mediated inflammatory disease characterized by itchy, painful, disfiguring and disabling skin lesions that impact one’s physical, emotional and psychological wellbeing.1-7 Globally, an estimated 64 million people are living with psoriasis and about 80-90% of those have plaque psoriasis.8-9 Persistent itch, the appearance and location of skin lesions – especially in highly visible or sensitive areas – and related comorbidities, like psoriatic arthritis, play a major role in reducing quality of life and can lead to significant impacts on daily living.4-7 Psoriasis is also a heterogeneous disease driven by complex, interconnected immune pathways, genetics and environmental factors that differ across patients and over time, leading to variability in disease course, symptoms and treatment response.10-14

About Zasocitinib (TAK-279)

Zasocitinib is an investigational, next-generation, highly selective and potent oral TYK2 inhibitor that maintains 24-hour inhibition of IL-23 plus other core disease-driving immune pathways.15-19 It has the potential to be a leading oral treatment option for people living with psoriasis that may deliver rapid and durable skin clearance in a convenient once-daily pill.20 Zasocitinib has more than 1-million-fold greater selectivity for TYK2 compared to other JAK enzymes, which could maximize TYK2 inhibition without impacting JAK1, 2 and 3 signaling, based on in vitro data.15-16 Takeda is currently evaluating the safety and efficacy of zasocitinib in Phase 3 studies in psoriatic arthritis, and Phase 2 studies in Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa (HS).21-27 Zasocitinib is an investigational compound that has not been approved for use by any regulatory authority.

About the LATITUDE Atlas Study

The LATITUDE Atlas (NCT06973291 / TAK-279-PsO-3004) study is a Phase 3, randomized, multicenter, double-blind trial evaluating the efficacy, safety and tolerability of zasocitinib compared to deucravacitinib in adult participants with moderate-to-severe plaque psoriasis.28 The study enrolled 606 participants, who received zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily up to week 16.28 Participants were in the study for up to 25 weeks, which included a screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period. The primary endpoint was the percentage of participants achieving PASI 100 at week 16.28

About Tyrosine Kinase 2 (TYK2) Inhibitors

TYK2 is a central mediator of core inflammatory pathways in psoriasis – IL-23/IL-17 axis and type I interferon signaling – making it a promising target as inhibition of a single pathway may not fully control disease for every patient.14,18,29 TYK2 is an intracellular enzyme and member of the Janus kinase (JAK) protein family.14-15 However, TYK2 is distinct from JAK1, 2 and 3 as it primarily regulates immune responses, whereas JAK1, 2 and 3 regulate broader biological processes such as lipid metabolism and hematopoiesis, which can be linked to cardiovascular risks and blood disorders when disrupted.14-15,30 Highly selective allosteric inhibition of TYK2, with minimal inhibition of JAK1, 2 and 3, is a promising therapeutic approach to target immune-mediated inflammation while potentially avoiding risks associated with inhibition of other members of the JAK family.19

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References

Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–23.

Bhosle, MJ, Kulkarni A, et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;35(4). https://doi.org/10.1186/1477-7525-4-35.

Dhabale A, Nagpure S. Types of psoriasis and their effects on the immune system. Cureus. 2022 Sep 24;14(9):e29536. doi: 10.7759/cureus.29536.

Taliercio VL, Snyder AM, Webber LB, et al. The Disruptiveness of Itchiness from Psoriasis: A Qualitative Study of the Impact of a Single Symptom on Quality of Life. J Clin Aesthet Dermatol. 2021;14(6):42-48.

Snyder AM, Taliercio VL, Webber LB, et al. The Role of Pain in the Lives of Patients with Psoriasis: A Qualitative Study on an Inadequately Addressed Symptom. J Psoriasis Psoriatic Arthritis. 2022 Jan;7(1):29-34. doi: 10.1177/24755303211066928. Epub 2021 Dec 12. PMID: 39296728; PMCID: PMC11361505.

Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in Special Localizations. Reumatologia. 2018;56(6):392-398. doi:10.5114/reum.2018.80718.

Blackstone B, Patel R, Bewley A. Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician. Psoriasis (Auckl). 2022;12:25-33.doi:10.2147/PTT.S32844

AIQassimi S, AIBrashdi S, Galadari H, Hashim MJ. Global Burden of Psoriasis - Comparison of Regional and Global Epidemiology, 1990 to 2017. Int J Dermatol. 9. 2020;59(5):566-571. doi: 10.llll/ijd.14864.

Mehta S, Sathe NC. Plaque Psoriasis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; September 14, 2025. https://www.ncbi.nlm.nih.gov/books/NBK43087.

Narayanan S, Guyatt V, Franceschetti A, Hautamaki EL. Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study. Psoriasis (Auckl). 2014;5:1-7. Published 2014 Dec 23. doi:10.2147/PTT.S74906

Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113. doi:10.1016/j.jaad.2018.11.058.

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 221;397(10281):1301-1315. doi:10.1016/S0140-6736(20)32549-6.

Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111-1119. doi:10.1111/jdv.14868

Muromoto R, Oritani K, Matsuda T. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J Biol Chem. 2022;13(1):1–14. doi:10.4331/wjbc.v13.i1.1.

Leit S, Greenwood J, Carriero S, et al. Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279. J Medicinal Chemistry.2023;66(15):10473-10496.doi.org/10.1021/acs.jmedchem.3c00600.

Mehrotra S, Sano Y, Halkowycz P, et al. Pharmacological characterization of zasocitinib (TAK-279): an oral, highly selective and potent allosteric TYK2 inhibitor. J Invest Dermatol. 2026;146:214-222.e7. https://www.jidonline.org/action/showPdf?pii=S0022-202X%2825%2900531-7.

Armstrong AW, Gooderham M, Lynde C, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. August 21, 2024. JAMA Dermatol. 2024 August 21;160;(10):1066- 1074. doi:10.1001/jamadermatol.2024.2701.

Shang L, et al. TYK2 in immune responses and treatment of psoriasis. J Inflamm Res. 2022;15:5373-5385. 2022 Sep 16. doi:10.2147/JIR.S38068.

Krueger JG, McInnes IB, Blauvelt A. Tyrosine Kinase 2 and Janus Kinase‒Signal Transducer and Activator of Transcription Signaling and Inhibition in Plaque Psoriasis. J Am Acad Dermatol. 2022;86(1):148-157. doi:10.1016/j.jaad.2021.06.869.

Gooderham M, et al. Once-daily Oral Zasocitinib Demonstrates Rapid and Reproducible Skin Clearance with a Consistent Safety Profile in Moderate-to-Severe Plaque Psoriasis: Results from Two Randomized Phase 3 Trials (LATITUDE-PsO-3001 and 3002). Presented at American Academy of Dermatology 2026. 2026 Mar 28; Denver, CO.

Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis | ClinicalTrials.gov Identifier: NCT07250802. Updated May 8, 2026. Accessed June 2026. https://clinicaltrials.gov/study/NCT07250802.

Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines. ClinicalTrials.gov Identifier: NCT06671483. Updated April 6, 2026. Accessed June 2026. https://clinicaltrials.gov/study/NCT06671483.

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines. ClinicalTrials.gov Identifier: NCT06671496. Updated April 6, 2026. Accessed June 2026. https://clinicaltrials.gov/study/NCT06671496.

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease. ClinicalTrials.gov Identifier: NCT06233461. Updated May 8, 2026. Accessed June 2026. https://clinicaltrials.gov/study/NCT06233461.

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis. ClinicalTrials.gov Identifier: NCT06254950. Updated May 6, 2026. Accessed June 2026. https://www.clinicaltrials.gov/study/NCT06254950.

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo. ClinicalTrials.gov Identifier: NCT07108283. Updated May 13, 2026. Accessed June 2026. https://clinicaltrials.gov/study/NCT07108283.

A Takeda Presentation. Quarterly Results - Quarter 1 FY2025. Available at: https://assets-dam.takeda.com/image/upload/v1753839858/Global/Investor/Financial-Results/FY2025/Q1/qr2025_q1_p01_en.pdf. Accessed June 2026.

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis. ClinicalTrials.gov Identifier: NCT06973291. Updated May 1, 2026. Accessed June 2026. https://clinicaltrials.gov/study/NCT06973291.

Martin G. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors. Dermatol Ther (Heidelb). 2023;13(2):417-435. doi:10.1007/s13555-022-00878-9.

Danese S, Peyrin-Biroulet L. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. Inflamm Bowel Dis. 2021;27(12):2023-2030. doi: 10.1093/ibd/izab135.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611341613/en/

Permalink

https://www.aetoswire.com/en/news/1106202655615

Contacts

Investor Relations

Christopher O’Reilly

takeda.ir.contact@takeda.com

Media Relations

Tsuyoshi Tada (Tokyo)

tsuyoshi.tada@takeda.com

Jennifer Henesey (Boston)

Jennifer.Henesey@takeda.com

 

Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments

 

• Results from Galderma’s global survey showed that performance is the top priority for healthcare professionals (HCPs), with long-lasting results, pure, highly active formulations, and fast onset cited as the leading criteria for recommending a treatment1
• Reliable clinical outcomes and robust clinical trials were the top two pillars of confidence for HCPs when selecting an anti-wrinkle treatment
• Ready-to-use liquid formulations are also gaining traction as a key treatment benefit when considering switching to new products1
• Patients also rank long-lasting and natural-looking results as the most important benefits when selecting a treatment, and cite increased confidence, improved appearance, and overall well-being as benefits they feel following treatment1

 

(BUSINESS WIRE)--Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product performance, and practitioner support.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610228460/en/

Anti-wrinkle treatments are among the most established procedures in aesthetic medicine and currently represent the most commonly performed nonsurgical cosmetic treatment worldwide.2 The market is set to expand further, with 85% of surveyed patients globally indicating they plan to maintain or increase their use in the future, including 97% in China and 87% in the UK.2 The insights from this survey are therefore especially valuable in understanding what patients and HCPs expect from the next generation of solutions.

HCPs prioritize performance: fast onset of action, long-lasting results, active formulations, and natural outcomes ranked as key features

Survey results showed HCPs are clear in their expectations for anti-wrinkle injectables: performance is paramount. When asked what features out of a list of eight would most influence their likelihood to purchase an anti-wrinkle treatment:1

• 73% ranked long-lasting results for at least six months within their top three features
• 64% ranked a highly active and pure formulation within their top three features
• 60% ranked fast onset of action, as early as Day 1 of treatment, within their top three features

Similarly, when asked to rate their top criteria for switching to a new product out of seven options:1

• 71% put long-lasting results for at least six months within their top three features
• 64% put highly active and pure formulations within their top three
• 56% put fast onset of action as early as Day 1 of treatment in their top three

When asked which key criteria (out of seven options) influence their selection for an anti-wrinkle treatment:1

• 90% of HCPs ranked reliable clinical outcomes in their top three
• 81% ranked robust clinical studies in their top three
• 80% ranked natural looking results as one of their most valued factors

Treatment ease-of-use, including streamlined workflows and reduced preparation time, is also gaining traction, including products in a ready-to-use liquid format, with HCPs giving this a score of 7.5/10 when asked to rank benefits of a treatment.1

Patients find value in long-lasting and natural-looking results, and improved confidence

For patients, the value of anti-wrinkle aesthetic treatments lies in both emotional outcomes and tangible performance, with long-lasting and early visible results top priorities:1

• When asked which features (out of seven options) they would be willing to pay more for in anti-wrinkle treatments, 78% put long-lasting results for at least six months within their top three
• With more than 70% of patients only receiving treatment once or twice a year, the need for long-lasting results matches real-life treatment patterns
• Patients gave early visible results as early as Day 1 of treatment a score of more than 8/10 when ranking important benefits of anti-wrinkle treatments

When asked to select up to three benefits (out of five options) they feel or notice after treatment, patients most frequently cited confidence, better appearance, and overall well-being, highlighting the deep emotional impact of anti-wrinkle treatment.1 86% of patients also noted natural-looking results within their three most valued benefits of anti-wrinkle treatment (out of a choice of seven), followed by reliable outcomes and – as with HCPs – long-lasting results.1

 

“These survey findings strongly reflect what we see in clinical practice and hear from our patients every day. When it comes to anti-wrinkle treatments, the top priorities are clear: patients want results that last and they want to see those results quickly. These expectations are shaping how we approach treatment planning and product selection, ensuring that evolving aesthetic solutions are more personalized, effective, and grounded in real-world patient needs.”

 

DR. SACHIN SHRIDHARANI

PLASTIC SURGEON AND FOUNDER OF LUXURGERY

NEW YORK CITY, U.S.

 

The survey engaged 280 patients and 162 HCPs, including dermatologists, plastic surgeons, aesthetic physicians, and nurse injectors.1 Patient participants had either received an anti-wrinkle injectable treatment in the past 12 months or were actively planning treatment within the next three months.1

Building a dermatology powerhouse

Galderma is on a clear path to become the world’s undisputed dermatology powerhouse spanning the full spectrum of this fast-growing market through Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.

The results provide timely, actionable insights from both patients and HCPs, reinforcing Galderma’s commitment to high-performance aesthetic solutions. As the anti-wrinkle injectable market continues to expand, these findings position Galderma at the forefront of innovation, shaping the future of aesthetics with science, precision, and purpose.

In Injectable Aesthetics, Galderma is firmly positioned on a trajectory to global leadership – not only in sales and market share, but also in innovation – supported by fully integrated in-house capabilities across discovery, research, development, manufacturing, and commercialization of best-in-class products.

We will continue to build on this momentum with our robust pipeline, expanding the number of early assets in the pipeline. Galderma leads the industry in the number of active aesthetic development programs, further reinforcing our leadership position in the U.S. and globally.

Galderma has the largest and most innovative portfolio on the market. Given our robust market positioning, we consider ourselves to be exceptionally well placed to take advantage of opportunities in this fast-growing market.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

Galderma. Data on File. Anti-wrinkle treatment Aesthetic Future Survey

Sundaram et al. Global Aesthetics Consensus: Botulinum Toxin Type A—Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast Reconstr Surg. 2016;137(3):518–529.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610228460/en/

Permalink

https://www.aetoswire.com/en/news/1106202655582

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

Visa Partners with OpenAI to Power the Next Generation of AI Commerce

 New collaboration brings Visa’s global payment network to one of the largest AI platforms and aims to support seamless, secure transactions and broader AI-powered use cases across commerce environments supported by agents

 

(BUSINESS WIRE)--Visa (NYSE: V) today announced a strategic collaboration with OpenAI to enable secure Visa payments within agentic commerce, enabling seamless and trusted payments across OpenAI. The companies made the announcement at the Visa Payments Forum in San Francisco. Through the partnership, Visa will provide its global network, credentialing capabilities and security infrastructure to support agentic commerce experiences, helping consumers and businesses interact and transact with confidence.

The collaboration is part of the broader Visa Intelligent Commerce initiative, which is focused on extending secure payment capabilities into new digital environments. Together, Visa and OpenAI will also explore a range of enterprise applications, including developer-focused experiences powered by Codex, as well as more automated and conversational workflows, as AI continues to evolve as an important interface for digital interactions.

As part of the partnership, Visa’s payment capabilities will be integrated into OpenAI experiences, giving developers and merchants a streamlined way to accept Visa payments initiated by agents. Alongside OpenAI, Visa will deliver the underlying network, tokenization and risk capabilities that support trusted and secure transactions.

Transactions will operate within clearly defined user permissions, policies and controls, such as spending limits, merchant categories or required approvals. Transactions will use tokenized Visa credentials and real-time authorization and fraud monitoring, helping enable new AI-enabled payment experiences to maintain strong security and consumer protection.

“AI will transform commerce more profoundly than the internet or mobile technology ever did,” said Jack Forestell, Chief Product and Strategy Officer, Visa. “As AI agents become active participants in the economy, Visa’s focus is to ensure transactions are trusted, secure and seamless. That’s the infrastructure we’re building with partners like OpenAI.”

“Commerce is going to happen in many more places and in many more ways than it does today, and agents will play an increasingly important role in helping people complete tasks that involve money—from purchases and payments to more complex transactions,” said Marco Mahrus, Head of Partnerships, Commerce at OpenAI. “By integrating with Visa Intelligent Commerce, we're building the infrastructure for secure, transparent, and user-controlled agentic transactions, helping people do more with AI agents while maintaining confidence that payments are being handled safely and securely.”

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610422687/en/

Permalink

https://aetoswire.com/en/news/1106202655579

Contacts

Media Contacts

Press@visa.com

Jackie Dresch

Conor Febos

TestMu AI Announces Day-Zero Support for macOS Golden Gate and iOS 27 Beta Following WWDC 2026

 SAN FRANCISCO & NOIDA, India -

Developers can now test websites, web applications, and mobile apps on Apple's latest operating systems before their public release

 

(BUSINESS WIRE)--TestMu AI (formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced day-zero support for Apple's newly unveiled operating systems, macOS Golden Gate and iOS 27 Beta, across its cloud testing platform.

Announced at Apple's Worldwide Developers Conference (WWDC) 2026, macOS Golden Gate and iOS 27 introduce significant platform updates that will impact application compatibility, user experience, and performance. Both operating systems are now available for testing on TestMu AI, the same day Apple released its beta versions, allowing engineering teams to identify issues months before the stable rollout reaches millions of users worldwide.

macOS Golden Gate is available through the TestMu AI Real Time Testing platform, while iOS 27 Beta is available on TestMu AI Real Device Cloud across the latest iPhones and iPads.

"WWDC marks the start of a critical testing window for every team that ships on Apple platforms," said Mudit Singh, Co-Founder & Head of Growth, TestMu AI. We introduced day-zero support so teams can begin testing immediately, without setting up or maintaining their own infrastructure. Developers and testers can validate their websites and applications on macOS Golden Gate and iOS 27, identify breaking changes early, and approach the public rollout with full visibility into how their websites and mobile apps behave."

Apple's latest OS, macOS Golden Gate, introduces several platform-level changes that developers must account for during testing. macOS Golden Gate completes Apple's transition away from Intel processors, becoming the first macOS release to support Apple Silicon exclusively. It also introduces a smarter Siri with Apple Intelligence, a rebuilt Spotlight and search foundation that indexes new data almost immediately, Liquid Glass design refinements, accessibility improvements, and expanded display support.

Meanwhile, iOS 27 focuses on performance optimization and platform refinement, with a modified CPU scheduler that improves responsiveness on older devices, upgraded Maps Flyover imagery, full-resolution iCloud Shared Albums that also work across Android and Windows, expanded parental controls through Child Accounts, and further refinements to the Liquid Glass design system. iOS 27 supports the same devices as iOS 26, covering models from the latest iPhones down to the iPhone 11.

With TestMu AI Real-Time Testing, developers can immediately validate websites and web applications across Safari, Chrome, and Firefox on macOS Golden Gate Beta.

For mobile application testing, TestMu AI Real Device Cloud provides access to real devices running iOS 27, where teams can validate gestures, GPS-based functionality, network behavior under varying connectivity conditions, push notifications, and other OS-dependent experiences that cannot be accurately replicated in simulators.

"As operating systems become more sophisticated, the gap between simulator behavior and real-world device behavior continues to grow," Singh added. "Testing on actual devices running beta operating systems helps teams identify issues early, reduce release risk, and deliver a seamless experience when users upgrade."

About TestMu AI

TestMu AI (Formerly LambdaTest) is a Full-Stack Agentic AI Quality Engineering platform that empowers teams to test intelligently and ship faster. Engineered for scale, it offers end-to-end AI agents to plan, author, execute, and analyze software quality. AI-native by design, the platform enables testing of web, mobile, and enterprise applications at any scale across real devices, real browsers, and custom real-world environments.

For more information, visit www.testmuai.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610631649/en/

Permalink

https://www.aetoswire.com/en/news/1106202655581

Contacts

Media Contact

Nikhil Saxena

Press and Media Manager

TestMu AI

nikhils@testmuai.com

 

Merrithew® Expands Global Mindful Movement Leadership with Acquisition of the GYROTONIC® Organization

 Strategic acquisition strengthens Merrithew International Inc.’s position as a leading global authority in mindful movement education, equipment, and wellness

(BUSINESS WIRE) -- Merrithew®, a global leader in mindful movement education and equipment and creator of internationally recognized programs including STOTT PILATES®, ZEN•GA®, Halo® Training and Total Barre®, today announced the acquisition of the GYROTONIC® organization, creator of the globally respected GYROTONIC® and GYROKINESIS® methods.

Founded by Juliu Horvath, the GYROTONIC® and GYROKINESIS® methods are internationally recognized for their distinctive approach to movement, combining fluidity, strength, mobility, coordination, and rehabilitation through specialized equipment and movement sequences. Practiced in studios and wellness centers worldwide, the methods have cultivated a deeply loyal global community of instructors, trainers, therapists, and movement professionals.

The acquisition marks a significant milestone in Merrithew International Inc.’s growth strategy and reflects Merrithew’s commitment to growing the rapidly expanding global mindful movement category. The addition of the GYROTONIC® organization strengthens Merrithew’s ability to serve instructors, studios, wellness professionals, and movement enthusiasts with an expanded portfolio of education, training, and equipment rooted in quality and specialized whole-body movement.

“This is an incredibly meaningful moment for Merrithew and the broader mindful movement community. The addition of GYROTONIC® expands Merrithew’s global reach, deepens our movement education portfolio, and reinforces our long-term vision of changing lives through mindful movement,” said Jim Heidenreich, CEO of Merrithew. “We are honored to support the continued growth of the GYROTONIC® and GYROKINESIS® methods, while preserving the philosophy, education standards, and community that have defined the organization since its founding.”

About Merrithew®

Merrithew® is the global leader in mindful movement, the company behind the STOTT PILATES® Movement System™ and the worldwide community built around it. Since 1988, they've trained over 90,000 instructors in more than 135 countries and developed premium equipment and science-based education trusted by leading studios, rehab centers, and fitness professionals. Merrithew supports instructors, studio owners and wellness leaders with a complete ecosystem to thrive, including training, equipment, digital resources, business tools, and a global network of peers. Their vision is to transform lives through intentional, inclusive movement, shaping the next era of mindful movement with innovation, purpose and a commitment to professional excellence. Merrithew.com.

About the GYROTONIC® Organization

Founded by Juliu Horvath, the GYROTONIC® organization is the creator of the internationally recognized GYROTONIC® and GYROKINESIS® methods. Known for their fluid, three-dimensional movement approach, the methods are practiced globally across fitness, wellness, rehabilitation and performance communities. Through a worldwide network of authorized studios and trainers, the organization has built a respected global community dedicated to intelligent movement, strength, mobility and holistic wellness.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611447598/en/

Permalink

https://www.aetoswire.com/en/news/1106202655621

Contacts

communications@merrithew.com

 

SES to conduct share buyback transaction via acquisition of FDRs to meet obligations under its employee incentive programs

LUXEMBOURG - Wednesday, 10. June 2026

Publication of inside information pursuant to Article 17 of Regulation (EU) No 596/2014 (MAR)

(BUSINESS WIRE) -- SES has decided to launch a buyback transaction for shares via acquisition of fiduciary depositary receipts (FDRs) to meet obligations under SES’s Equity Based Compensation Plan (EBCP). These FDRs will be repurchased on the basis of Article 430-15(3) of the law of 10 August 1915 on commercial companies, as amended, and will not be counted towards the 10% limit as authorized during the annual general meeting of shareholders held on April 2, 2026.

Under this share buyback transaction via acquisitions of FDRs, SES may acquire up to 2,967,519 FDRs (ISIN LU0088087324) at market price for an aggregate amount not exceeding EUR 31,158,949.50. The share buyback transaction via acquisition of FDRs is expected to be completed before the date of the next annual general meeting of shareholders or sooner if the maximum number of repurchased shares is reached earlier.

The buyback will be conducted in accordance with applicable rules and regulations, including the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052. The buyback program will be executed by an independent intermediary, Société Generale. The timing of the buyback will depend on a variety of factors, including market conditions.

About SES

At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry leadership—backed by a track record of bringing innovation “firsts” to market. As a trusted partner to customers and the global space ecosystem, SES is driving impact that goes far beyond coverage. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610664333/en/

Permalink
https://www.aetoswire.com/en/news/1006202655563

Contacts

Steven Lott
Communications
Tel. +352 710 725 500
SES.Press@ses.com

Bitget Launches Anti-Scam Month 2026, Recovers $32.3 Million for Users

 

VICTORIA, Seychelles - Tuesday, 09. June 2026

Bitget, the world’s largest Universal Exchange (UEX), has launched Anti-Scam Month 2026 under the theme “More Assets, Stronger Shield. Stay Safe in the Multi-Asset Era.” The annual initiative focuses on helping users navigate an increasingly complex threat landscape as digital asset platforms expand beyond crypto into broader multi-asset ecosystems.

The campaign is accompanied by the release of key security and fraud prevention results from 2025. During the year, Bitget intercepted more than 150 million malicious attack requests, identified over 13,000 high-risk malicious IP addresses, and handled 18,135 user protection cases. The platform’s security team also helped users recover approximately $32.3 million linked to security incidents and fraudulent activity.

“The industry is entering a multi-asset era where users can access a wider range of products and markets through a single platform. As that access expands, security responsibilities increase too,” said Hon Ng, Chief Legal Officer at Bitget. “Protecting users requires continuous risk monitoring, rapid response mechanisms, security education, and close cooperation across the industry. Anti-Scam Month reflects the importance of building those protections alongside product innovation.”

Throughout 2025, Bitget continued to strengthen its security framework across account protection, asset custody, fraud prevention, and platform risk management. The platform expanded Passkey authentication capabilities based on FIDO2 and WebAuthn standards, enhanced multi-factor authentication coverage for high-risk account actions, strengthened anti-phishing protections, and improved device management controls that allow users to monitor and manage account access in real time.

Bitget also expanded its real-time threat detection and web security infrastructure in 2025. Security systems recorded more than 2.8 billion interceptions through custom protection rules and mitigated over 1.5 billion DDoS-related attack attempts. The platform’s monitoring capabilities were further enhanced through machine learning-based behavioral analysis designed to identify suspicious activity and emerging threats across multiple layers of the ecosystem.

User education remained a major focus of Bitget’s security strategy. Anti-Scam Month campaigns conducted across 2024 and 2025 reached approximately 1.38 billion users globally through security awareness content, educational resources, and community engagement initiatives. The company also expanded its Anti-Scam Hub, maintained its public bug bounty program, and introduced interactive initiatives such as the Smarter Eyes Challenge, which attracted close to 50,000 participants through simulated phishing and scam detection exercises.

Bitget continued to collaborate with leading blockchain security organizations, including SlowMist and Elliptic, to support threat intelligence sharing, anti-fraud research, and broader industry awareness efforts. Through a combination of platform security, user education, and industry cooperation, the company continues to invest in creating a safer environment for users navigating digital and tokenized financial markets.

Read our CLO’s letter here: https://www.bitget.com/blog/articles/bitget-clo-letter-more-assets-mean-more-responsibility

For more information, visit: https://www.bitget.com/events/antiscamhub

About Bitget

Bitget is the world’s largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 100+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships with LALIGA and MotoGP™. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry’s lowest fees and highest liquidity across 150 regions worldwide.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/cb6574f4-b2ab-4d1a-911f-2be535c75afc

Contacts :

For media inquiries, please contact: media@bitget.com

Solana Becomes Presenting Sponsor of the World Series of Poker®

 WSOP to Bring Crypto to Global Events Through Solana-Powered Tournament Ticket Purchases

(BUSINESS WIRE) -- The World Series of Poker (WSOP®), the longest-running and most prestigious poker tournament series in the world, today announced a first-of-its-kind collaboration with the Solana Foundation to bring crypto directly into the global poker experience.

Beginning today at the 57th annual summer event at Paris Las Vegas and Horseshoe Las Vegas, players will be able to purchase tournament tickets using Solana, powered by MoonPay’s payment infrastructure. This will be the first time in WSOP history where players can buy tournament tickets directly with crypto, and by leveraging Solana’s technology, this payment method will have zero processing fees.

The integration will expand further at the 2026 WSOP Paradise in The Bahamas this December, where tournament winners can receive settlements in stablecoins on Solana, enabling near-instant access to payments and reducing the friction traditionally associated with international tournament settlements.

As part of this collaboration, Solana Foundation will also serve as the official Presenting Sponsor of the 2026 World Series of Poker and 2026 World Series of Poker Paradise.

The World Series of Poker, Dealt by Solana

The poker community has long been at the forefront of digital currency adoption, with players embracing decentralized technology, like Solana, for its efficiency and transparency. As a high-performance blockchain, Solana is celebrated for its industry-leading transaction speeds - capable of processing thousands of transactions per second - and ultra-low costs, with average fees remaining below $0.001. By enabling players to make purchases through MoonPay, and cashout in stablecoins on Solana, these initiatives allow:

Faster settlement and streamlined payment processing for eligible events

Greater accessibility for international players traveling to WSOP events

Near-instant global settlement, with reduced friction for users

Expanded payment flexibility for players participating in marquee tournaments worldwide

Introducing Solana-powered purchases and settlements modernizes how money moves through the poker ecosystem and reduces friction for players around the world.

Where Poker and Crypto Converge

This initiative bridges the digital asset space and the poker world, reinforcing the growing demand among players for faster financial tools that simplify participation in global events. Beyond payments, the collaboration brings together communities that are closely aligned.

"We are incredibly proud to bring such an innovative and passionate community into the fold," said Ty Stewart, Chief Executive Officer of WSOP. "Solana’s ecosystem, like the WSOP, constantly challenges conventions and remains laser-focused on the consumer experience. Solana’s speed and efficiency mirror the fast-paced energy of our tournaments, and we are excited to showcase their technology to our global audience."

“Solana is a digital economy where people can own and trade millions of assets, make payments, earn on their money, and more,” said Vibhu Norby, Chief Product Officer, Solana Foundation. “Trading in particular has been a huge area of growth on Solana over the last few years, generating over $4 trillion in volume. At its core, trading shares many of the same characteristics as poker: hard decisions, incomplete information, minding your bankroll. We’re incredibly excited to grow the game of poker with the WSOP and bring these two worlds together.”

"Poker players have always lived at the forefront of innovation. They think in probabilities, move fast, and adopt the tools that give them an edge," said Jim Walker, President of MoonPay Commerce. "Crypto is a natural fit. By powering ticket purchases and settlements through MoonPay on Solana, we're meeting that demand directly: faster, borderless payments that make it simple for players anywhere to take their seat at the world's biggest tables."

Beyond the Felt: Ambassadors and Hospitality

The Solana Foundation is set to sponsor a select group of individual poker player ambassadors who will represent the ecosystem at this summer’s WSOP event. Additionally, the Solana ecosystem will host exclusive hospitality events at the Paris and Horseshoe venues in Las Vegas, as well as a premier experience during WSOP Paradise in The Bahamas this winter. Solana users can also look forward to collaborative onchain poker products, developed with WSOP, to follow.

Thrilling WSOP action is streamed daily on the WSOP YouTube channel and on X via @Solana. The WSOP 2026 Main Event will also return to linear TV in the United States on ESPN from July 2, and worldwide to more than 130 countries and over 300 million homes via ESPN networks, TSN, Disney+, Groupe M6, Abema Japan and Warner Bros. Discovery’s Eurosport.

Players should follow @WSOP on X (formerly Twitter) and Instagram or check WSOP.com for more news and updates on this year’s WSOP event. For more information on Solana, please visit solana.com.

About World Series of Poker

The World Series of Poker® is the largest, richest and most prestigious gaming event and poker brand in the world, having awarded more than $4 billion in prize money over the past six decades. Featuring a comprehensive slate of tournaments in every major poker variation, the WSOP is poker’s longest-running tournament dating back to 1970. In 2025, the flagship event in Las Vegas attracted 246,960 entrants and awarded more than $481 million in prize money – both all-time records for the series. The WSOP portfolio of events includes approximately 50 WSOP Circuit Events annually across five continents, WSOP Europe (since 2007), WSOP Paradise (since 2023) and the record-breaking WSOP Online festival. International satellites to WSOP live events are hosted exclusively at GGPoker, the World’s Biggest Poker Room. For more information, please visit www.wsop.com.

About Solana

Solana is a high performance network powering internet capital markets, payments, AI agents, and crypto applications. Solana operates as a single global state machine, and is open, interoperable and decentralized. For more information, please visit https://solana.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610344534/en/

Permalink

https://www.aetoswire.com/en/news/1006202655572

Contacts

Media Contacts:

WSOP

press@wsop.com

Solana Foundation

press@solana.org